elranatamab
pfizer
['magnetismm-3', 'multiple myeloma', 'multiplemyeloma', 'pfizer']
today at #ash22, we shared updated data on our magnetismm-3 trial evaluating our investigational bcma-directed bispecific antibody treatment for people with #multiplemyeloma. learn more: 
The official Twitter channel dedicated to media announcements & investor communications from Pfizer Inc. To see all of our Tweets, please follow @pfizer.